Nektar Therapeutics Company Profile (NASDAQ:NKTR)

Analyst Ratings

Consensus Ratings for Nektar Therapeutics (NASDAQ:NKTR) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.25 (13.35% upside)

Analysts' Ratings History for Nektar Therapeutics (NASDAQ:NKTR)
Show:
DateFirmActionRatingPrice TargetActions
6/1/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Piper Jaffray Cos.Reiterated RatingBuy$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/12/2016William BlairReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016Janney Montgomery ScottInitiated CoverageBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2015JPMorgan Chase & Co.Lower Price TargetOverweight$19.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2015Jefferies GroupLower Price TargetBuy$17.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/17/2014Bank of America Corp.Reiterated RatingUnderperform$10.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Nektar Therapeutics (NASDAQ:NKTR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/3/2016Q1($0.23)($0.14)$43.78 million$58.88 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/1/2016Q4($0.42)($0.40)$28.82 million$39.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.24)($0.06)$44.30 million$60.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.40)($0.40)$21.49 million$22.66 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115($0.40)$0.25$20.20 million$108.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q414($0.36)($0.35)$12.30 million$19.55 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314$0.39$0.53$123.20 million$132.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q214($0.37)($0.26)$19.76 million$28.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014Q114($0.19)($0.37)$38.68 million$19.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2014Q413($0.17)($0.41)$49.26 million$31.15 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313($0.22)($0.14)$54.34 million$60.91 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.44)($0.37)$26.22 million$33.86 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.42)($0.48)$26.30 million$23.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2012Q312($0.39)($0.38)$21.02 million$18.41 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2012($0.33)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2012($0.33)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2012($0.47)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2011($0.37)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2011($0.31)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/27/2011($0.27)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nektar Therapeutics (NASDAQ:NKTR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.36)($0.14)($0.23)
Q2 20162($0.35)($0.31)($0.33)
Q3 20163($0.34)($0.27)($0.30)
Q4 20163($0.31)($0.17)($0.23)
Q1 20171($0.21)($0.21)($0.21)
Q2 20171($0.21)($0.21)($0.21)
Q3 20171($0.21)($0.21)($0.21)
Q4 20171($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Nektar Therapeutics (NASDAQ:NKTR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Nektar Therapeutics (NASDAQ:NKTR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/11/2016Jillian B ThomsenCAOSell100,000$15.09$1,509,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2016Robert ChessDirectorSell5,000$14.10$70,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2016Gil M LabrucherieSVPSell836$13.58$11,352.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2016Howard W RobinCEOSell2,170$13.58$29,468.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2016Jillian B ThomsenCAOSell724$13.58$9,831.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2016John NicholsonCFOSell856$13.58$11,624.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/25/2016Lutz LingnauDirectorSell15,000$16.27$244,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Howard W. RobinCEOSell2,147$11.92$25,592.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Jillian B. ThomsenCAOSell716$11.92$8,534.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Maninder HoraSVPSell963$11.92$11,478.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2016Gil M. LabrucherieSVPSell11,666$11.49$134,042.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2016Howard W. RobinCEOSell66,666$11.49$765,992.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2016Jillian B. ThomsenCAOSell15,000$11.49$172,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2016Lutz LingnauDirectorSell15,000$14.51$217,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Gil M. LabrucherieSVPSell11,667$14.12$164,738.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Howard W. RobinCEOSell66,667$14.12$941,338.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Jillian B. ThomsenCAOSell15,000$14.12$211,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2015Christopher A. KueblerDirectorSell15,000$15.82$237,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015Gil M. LabrucherieSVPSell45,001$15.87$714,165.87View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015Howard W. RobinCEOSell125,001$15.87$1,983,765.87View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015Jillian B. ThomsenCAOSell15,000$15.87$238,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2015Susan WangDirectorSell85,000$15.02$1,276,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Gil M. LabrucherieSVPSell45,000$13.52$608,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Howard W. RobinCEOSell125,000$13.52$1,690,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Jillian B. ThomsenCAOSell15,000$13.52$202,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/28/2015Lutz LingnauDirectorSell12,500$12.00$150,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Gil M. LabrucherieSVPSell45,000$10.99$494,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Howard W. RobinCEOSell125,000$10.99$1,373,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Jillian B. ThomsenCAOSell15,000$10.99$164,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2015Gil M. LabrucherieSVPSell44,999$13.04$586,786.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2015Howard W. RobinCEOSell124,999$13.04$1,629,986.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2015Jillian B. ThomsenCAOSell10,000$13.04$130,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Gil M LabrucherieSVPSell33,333$10.89$362,996.37View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Howard W RobinCEOSell58,333$10.89$635,246.37View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2015Gil M LabrucherieSVPSell33,334$11.78$392,674.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2015Howard W RobinCEOSell58,334$11.78$687,174.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/29/2015Susan WangDirectorSell30,000$12.70$381,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Robert ChessDirectorSell15,000$11.81$177,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Lutz LingnauDirectorSell25,000$11.15$278,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014Robert ChessDirectorSell29,500$15.34$452,530.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2014Jillian B ThomsenCAOSell5,000$15.56$77,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Gil M LabrucherieSVPSell120,000$17.02$2,042,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Howard W RobinCEOSell350,000$17.01$5,953,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Howard W RobinCEOSell600,000$15.25$9,150,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Gil M LabrucherieSVPSell10,500$15.04$157,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Howard W RobinCEOSell132,800$15.02$1,994,656.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Lutz LingnauDirectorSell15,000$15.02$225,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Gil M LabrucherieSVPSell9,900$13.78$136,422.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2013Roy WhitfieldDirectorSell12,500$12.41$155,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2012Dennis L WingerDirectorBuy5,000$9.18$45,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Nektar Therapeutics (NASDAQ:NKTR)
DateHeadline
07/29/16 07:45 AMNektar Therapeutics (NKTR) Worth a Look: Stock Gains 6.1% -
07/28/16 05:42 PMNektar Therapeutics (NKTR) Jumps 6.13% on July 28 - Equities.com
07/28/16 08:40 AMNoticeable Analyst's ideas: Edwards Lifesciences Corporation (NYSE:EW) , Nektar Therapeutics (NASDAQ:NKTR) - Street Updates
07/27/16 04:28 PMNektar to Announce Financial Results for the Second Quarter 2016 on Wednesday, August 3, 2016, After Close of U.S.-Based Financial Markets - [at noodls] - SAN FRANCISCO, July 27, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2016, on Wednesday, August 3, 2016, after the close ...
07/27/16 08:28 AMSummary of Analyst's Study: Dr. Reddy's Laboratories Ltd (NYSE ... - Street Updates
07/26/16 05:46 PMNektar Therapeutics (NKTR) Shares are Down -1.62% - Trade Calls
07/23/16 05:01 PMAnalysts Review of Stocks: Endo International (NASDAQ:ENDP) , Nektar Therapeutics (NASDAQ:NKTR) - Street Updates
07/21/16 05:45 PMEarnings Focus and Crowd Sourced Sentiment Review for Nektar Therapeutics (NASDAQ:NKTR) - TGP
07/21/16 08:21 AMAegerion to Withdraw Juxtapid from EU, Reduces Workforce
07/20/16 08:23 AMNektar Therapeutics (NASDAQ:NKTR): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 08:23 AMShares Positive Over the Past Month: Nektar Therapeutics (NASDAQ:NKTR) - TGP
07/19/16 05:33 PMBristol-Myers' Opdivo Label Expansion Under U.S., EU Review
07/19/16 05:33 PMForm 4 NEKTAR THERAPEUTICS For: Jul 14 Filed by: Thomsen Jillian B.
07/19/16 08:35 AMShare Performance Summary for: Nektar Therapeutics (NASDAQ:NKTR) - Press Telegraph
07/18/16 05:35 PMTrading Performance and Target Watch for Nektar Therapeutics (NASDAQ:NKTR) - Press Telegraph
07/18/16 05:35 PMIs $20 Price Target Attainable For Nektar Therapeutics (NASDAQ:NKTR)? - Investor Newswire
07/18/16 05:35 PMShares of Nektar Therapeutics (NKTR) Rally 3.55% - Trade Calls
07/15/16 10:17 AMHot Biotech Stocks Recap: Nektar Therapeutics (NASDAQ:NKTR), Halozyme Therapeutics, Inc. (NASDAQ:HALO) - The Voice Registrar
07/15/16 10:17 AMNektar Therapeutics (NKTR): Price Target and June Short Interest Disclosure - Trade Calls
07/14/16 09:01 AMCrowd Rating and Earnings Recap for Nektar Therapeutics (NASDAQ:NKTR) - Telanagana Press
07/13/16 05:49 PMIs Nektar Therapeutics (NASDAQ:NKTR) Stock a Sell after Jillian Thomsen's Insider Trading? - Press Telegraph
07/13/16 08:24 AMAnalyst Target and Average Rating Watch: Nektar Therapeutics (NASDAQ:NKTR) - Press Telegraph
07/12/16 09:49 AMNektar Therapeutics (NASDAQ:NKTR) Shorted Shares Decreased By 12.66% - Press Telegraph
07/11/16 05:29 PMStrong Sell Calls For Nektar Therapeutics (NASDAQ:NKTR) At 0 - Investor Newswire
07/11/16 10:04 AMStock Performance Rundown on: Nektar Therapeutics (NASDAQ:NKTR) - Press Telegraph
07/11/16 10:04 AMNext Weeks Broker Price Targets For Nektar Therapeutics (NASDAQ:NKTR) - Fiscal Standard
07/11/16 08:56 AMNektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : July 11, 2016 -
07/08/16 08:24 AMNektar Therapeutics (NKTR) : Analyst Rating Update - Trade Calls
07/06/16 02:07 PMThe Probable Reason Behind Nektar Therapeutics Inc.'s 15.5% Year-to-Date Drop -
07/06/16 10:04 AMDendrimers and Polymer Drug Conjugates Market, 2016 - 2026
07/05/16 09:59 AMDendrimers and Polymer Drug Conjugates Market (2016 - 2026) - 40 Polymer Drug Conjugates in Clinical Development - Research and Markets
07/04/16 10:08 AMShare Performance Recap for: Nektar Therapeutics (NASDAQ:NKTR) - Press Telegraph
07/04/16 10:08 AMCan Nektar Therapeutics (NASDAQ:NKTR) Meet Analysts Expectations? - Stocks Daily
07/02/16 08:13 AMNektar Therapeutics (NASDAQ:NKTR) Current Analyst Ratings - Fiscal Standard
06/28/16 05:22 PMShort Interest Falls 12.7% For NKTR
06/28/16 10:18 AMTop Stock Pick for Quarter: Nektar Therapeutics (NASDAQ:NKTR) - Engelwood Daily
06/28/16 10:18 AMEquity Research and Technical Review on Nektar Therapeutics (NASDAQ:NKTR) - Press Telegraph
06/28/16 10:18 AMStrong Sell Calls Recommendations For Nektar Therapeutics (NASDAQ:NKTR) At 0 - Investor Newswire
06/27/16 05:21 PMNektar Therapeutics (NASDAQ:NKTR) Broker Price Targets For The Coming Week - Fiscal Standard
06/27/16 03:46 PMNEKTAR THERAPEUTICS Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/27/16 10:16 AMNektar Therapeutics breached its 50 day moving average in a Bearish Manner : NKTR-US : June 27, 2016 -
06/27/16 09:41 AMStock Performance Focus on: Nektar Therapeutics (NASDAQ:NKTR) - Press Telegraph
06/25/16 09:11 AMNektar Therapeutics (NASDAQ:NKTR) Yearly Sales Target At $448.69 - Investor Newswire
06/23/16 08:10 AMDover Corporation (NYSE:DOV) Median EPS Target At $1.025
06/23/16 08:10 AMBIND Therapeutics : Pre-market Equity Watch on Biotechnology -- Infinity Pharma, Nektar Therapeutics, Aralez Pharma, and BIND Therapeutics
06/22/16 05:21 PMStrong Buy Calls Count For Nektar Therapeutics (NASDAQ:NKTR) At 7 - Investor Newswire
06/22/16 05:21 PMNektar Therapeutics (NASDAQ:NKTR) Analyst Rating Consensus - TheFounders Daily
06/20/16 05:20 PMNektar Therapeutics (NKTR) take heat post earnings
06/20/16 02:42 PMNektar Therapeutics – Value Analysis (NASDAQ:NKTR) : June 20, 2016 -
06/14/16 07:40 AMNektar Therapeutics breached its 50 day moving average in a Bearish Manner : NKTR-US : June 14, 2016 -

Social

About Nektar Therapeutics

Nektar Therapeutics logoNektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company's pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology. The Company's drugs include MOVANTIK (naloxegol) tablets, MOVENTIG, AdYnoVATE, NKTR-102 (next-generation topoisomerase I inhibitor), BAY41-6551 (Amikacin inhale, formerly NKTR-061), NKTR-181 (orally-available mu-opioid analgesic molecule), NKTR-102, NKTR-214 and MoVAnTiK fixed-dose combinations (opioid/naloxegol combinations). Its drugs also include Neulasta (pegfilgrastim), PEGASYS (peginterferon alfa-2a), PEG-INTRON (peginterferon alfa-2b), Somavert (pegvisomant) and Macugen (pegaptanib sodium injection).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: NKTR
  • CUSIP: 64026810
Key Metrics:
  • Previous Close: $16.10
  • 50 Day Moving Average: $15.00
  • 200 Day Moving Average: $13.99
  • P/E Ratio: N/A
  • P/E Growth: 2.19
  • Market Cap: $2.19B
  • Beta: 1.71
  • Current Year EPS Consensus Estimate: $-0.91 EPS
  • Next Year EPS Consensus Estimate: $-0.7 EPS
Additional Links:
Nektar Therapeutics (NASDAQ:NKTR) Chart for Friday, July, 29, 2016